Los Angeles Capital Management
PRME icon

Los Angeles Capital Management’s Prime Medicine PRME Stock Holding History

Los Angeles Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Buy
82,305
+29,690
+56% +$98.6K ﹤0.01% 1055
2026
Q1 		$183K Buy
+52,615
New +$200K ﹤0.01% 1169

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Los Angeles Capital Management's PRME Position: Q2 2026 in Review

Los Angeles Capital Management increased its Prime Medicine (PRME) stake by 56% in Q2 2026, buying an estimated $98.6K and bringing the position to 82,305 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #1055.

Los Angeles Capital Management first reported a position in PRME in Q1 2026 and has held it in 2 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Los Angeles Capital Management held 82,305 shares of Prime Medicine worth $304K as of Q2 2026.
  • Los Angeles Capital Management bought 29,690 Prime Medicine shares in Q2 2026, an estimated $98.6K.
  • Prime Medicine made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1055 holding.
  • Los Angeles Capital Management first reported a position in Prime Medicine in Q1 2026 and has held it in 2 quarters since.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.